PS
CRBU icon

Principal Securities’s Caribou Biosciences CRBU Stock Holding History

Principal Securities’s Portfolio CRBU Stock Details CRBU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-270
Closed -$629 – 1777
2025
Q3 		$629 Sell
270
-187
-41% -$353 ﹤0.01% 3496
2025
Q2 		$576 Sell
457
-500
-52% -$492 ﹤0.01% 3456
2025
Q1 		$1.52K Hold
957
– – ﹤0.01% 3108
2024
Q4 		$1.52K Hold
957
– – ﹤0.01% 3102
2024
Q3 		$1.88K Buy
957
+343
+56% +$702 ﹤0.01% 2970
2024
Q2 		$1.01K Sell
614
-19
-3% -$61 ﹤0.01% 3071
2024
Q1 		$3.25K Sell
633
-51
-7% -$314 ﹤0.01% 2736
2023
Q4 		$3.92K Buy
+684
New +$3.38K ﹤0.01% 2620

Other funds holding CRBU

P
Pfizer New York $239M AUM 232.47% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Principal Securities's CRBU Position: Q4 2025 in Review

Principal Securities sold out of Caribou Biosciences (CRBU) in Q4 2025, closing a stake of 270 shares — an estimated $629 sold.

Principal Securities first reported a position in CRBU in Q4 2023 and held it in 8 quarters. The position peaked at $3.92K in Q4 2023. 124 funds tracked by Wall St. Rank hold CRBU as of Q4 2025.

  • Principal Securities reported no remaining Caribou Biosciences position as of Q4 2025 after selling out during the quarter.
  • Principal Securities sold 270 Caribou Biosciences shares in Q4 2025, an estimated $629.
  • Principal Securities first reported a position in Caribou Biosciences in Q4 2023 and held it in 8 quarters.
  • Principal Securities's Caribou Biosciences position peaked at $3.92K in Q4 2023.
  • 124 funds tracked by Wall St. Rank held Caribou Biosciences as of Q4 2025.

Based on Principal Securities's 13F filing for Q4 2025, filed 12 Feb 2026.